Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 989-997

  Bohn, Kathrin ^a   Zell, Roland ^a   Schacke, Michael ^a   Wutzler, Peter ^a   Sauerbrei, Andreas ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DNA POLYMERASE; FOSCARNET; THYMIDINE KINASE;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CHILD; CONTROLLED STUDY; DNA POLYMERASE GENE; DNA SEQUENCE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THYMIDINE KINASE GENE; VIRUS GENE; VIRUS RESISTANCE;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; INFANT; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; THYMIDINE KINASE; VIRAL PROTEINS;

EID: 80055064700     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1852     Document Type: Article

References (39)

1. Basse G, Mengelle C, Kamar N, et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection 2008; 36:62-64.
2. Herget GW, Riede UN, Schmitt-Gräff A, Lübbert M, Neumann-Haefelin D, Köhler G. Generalized herpes simplex virus infection in an immunocompromised patient - report of a case and review of the literature. Pathol Res Pract 2005; 201:123-129. (Pubitemid 40443826)
3. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133. (Pubitemid 38582018)
4. Roizman B, Sears AE. In Fields BN, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA (Editors). Fields Virology: Herpes simplex viruses and their replication (3rd Edition). Philadelphia: Lippincott-Raven Publishers 1996; pp. 2231-2295.
5. Safrin S, Asseykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161:1078-1084. (Pubitemid 20177863)
6. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242-249. (Pubitemid 38082727)
7. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16:114-128. (Pubitemid 36114710)
8. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogenic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000; 181:2055-2058. (Pubitemid 30416174)
9. Morfin F, Thouvenout D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26:29-37. (Pubitemid 36183346)
10. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 2010; 86:246-252.
11. Larder BA, Darby G. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. Virology 1985; 146:262-271. (Pubitemid 16240381)
12. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. Genetic characterization of thymindine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 2000; 182:290-293. (Pubitemid 30497816)
13. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymindine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833-4842.
14. Sauerbrei A, Eichhorn U, Hottenrott G, Wutzler P. Virological diagnosis of herpes simplex encephalitis. J Clin Virol 2000; 17:31-36. (Pubitemid 30256289)
15. Klöcking R, Schacke M, Wutzler P. [Primary screening of antiherpetic compounds by the use of EZ4U]. Chemotherapie J 1995; 4:141-147. German
16. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovirresistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325:551-555.
17. McGeoch DJ, Dolan A, Donald S, Rixon FJ. Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. J Mol Biol 1985; 181:1-13. (Pubitemid 16217352)
18. McGeoch DJ, Moss HW, McNab D, Frame MC. DNA sequence and genetic content of the Hind III 1 region in the short unique component of the herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparison. J Gen Virol 1987; 68:19-38. (Pubitemid 17207186)
19. Suzutani T, Ishioka K, De Clercq E, et al. Differential mutation pattern in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. Antimicrob Agents Chemother 2003; 47:1707-1713. (Pubitemid 36548558)
20. Chiba A, Suzutani T, Sajo M, Koyano S, Azuma M. Analysis of nucleotide sequence variations in herpes simplex virus types 1 and 2, and varicella-zoster virus. Acta Virol 1998; 42:401-407. (Pubitemid 29180557)
21. Watson-Jones D, Wald A, Celum C, et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol 2010; 48:3496-3503.
22. Kudo E, Shiota H, Naito T, Satake K, Itakura M. Polymorphisms of thymindine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. J Med Virol 1998; 56:151-158. (Pubitemid 28419277)
23. Chibo D, Druce J, Sasadeusz J, Birch C. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 2004; 61:83-91. (Pubitemid 37506095)
24. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5:88-114. (Pubitemid 35024271)
25. Hwang YT, Liu BY, Coen DM, Hwang CB. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J Virol 1997; 71:7791-7798. (Pubitemid 27391725)
26. Gibbs JS, Weisshart K, Digard P. deBruynKops A, Knipe DM, Coen DM. Polymerization activity of an alphalike DNA polymerase requires a conserved 3′-5′ exonuclease active site. Mol Cell Biol 1991; 11:4786-4795. (Pubitemid 21895877)
27. Frobert E, Cortay JC, Ooka T, et al. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACVsensitive and 14 ACV-resistant viruses. Antiviral Res 2008; 79:28-36.
28. Stránská R, Schuurman R, Scholl DR, et al. ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing. Antimicrob Agents Chemother 2004; 48:2331-2333.
29. Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001; 75:3105-3110.
30. Duan R, de Vries RD, van Dun JM, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200:1402-1414.
31. Schulte EC, Sauerbrei A, Hoffmann D, Zimmer K, Hemmer B, Mühlau M. Acyclovir resistance in herpes simplex virus encephalitis. Ann Neurol 2010; 67:830-833.
32. Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplsx virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J Infect Dis 1999; 180:487-490. (Pubitemid 30256332)
33. Matthews JT, Terry BJ, Field AK. The structure and function of the HSV DNA replication proteins: defining novel antiviral targets. Antiviral Res 1993; 20:89-114. (Pubitemid 23024877)
34. Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003; 77:7820-7829. (Pubitemid 36792779)
35. Duffy KE, Quail MR, Nguyen TT, et al. Assessing the contribution of the herpes simplex virus DNA polymerase to spontaneous mutations. BMC Infect Dis 2002; 2:7.
36. Sarisky RT, Nguyen TT, Duffy KE, Wittrock RJ, Leary JJ. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 2000; 44:1524-1529. (Pubitemid 30340789)
37. Andrei G, Fiten G, Froeyen E, De Clercq E, Opdenakker G, Snoeck R. DNA polymerase mutations in drugresistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 2007; 12:719-732. (Pubitemid 47235486)
38. Stránská R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7-18. (Pubitemid 39575009)
39. Prichard MN, Quenelle DC, Hartline CB, et al. Inhibition of herpesvirus replication by 5-substituted 4′- thiopyrimidine nucleosides. Antimicrob Agents Chemother 2009; 53:5251-5258.